Literature DB >> 23689058

Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study.

Cheri Deal1, Caroline Hasselmann, Roland W Pfäffle, Alan G Zimmermann, Charmian A Quigley, Christopher J Child, Elena P Shavrikova, Gordon B Cutler, Werner F Blum.   

Abstract

BACKGROUND/AIMS: Magnetic resonance imaging (MRI) is used to investigate the etiology of growth hormone deficiency (GHD). This study examined relationships between MRI findings and clinical/hormonal phenotypes in children with GHD in the observational Genetics and Neuroendocrinology of Short Stature International Study, GeNeSIS.
METHODS: Clinical presentation, hormonal status and first-year GH response were compared between patients with pituitary imaging abnormalities (n = 1,071), patients with mutations in genes involved in pituitary development/GH secretion (n = 120) and patients with idiopathic GHD (n = 7,039).
RESULTS: Patients with hypothalamic-pituitary abnormalities had more severe phenotypes than patients with idiopathic GHD. Additional hormonal deficiencies were found in 35% of patients with structural abnormalities (thyroid-stimulating hormone > adrenocorticotropic hormone > luteinizing hormone/follicle-stimulating hormone > antidiuretic hormone), most frequently in patients with septo-optic dysplasia (SOD). Patients with the triad [ectopic posterior pituitary (EPP), pituitary aplasia/hypoplasia and stalk defects] had a more severe phenotype and better response to GH treatment than patients with isolated abnormalities. The sex ratio was approximately equal for patients with SOD, but there was a significantly higher proportion of males (approximately 70%) in the EPP, pituitary hypoplasia, stalk defects, and triad categories.
CONCLUSION: This large, international database demonstrates the value of classification of GH-deficient patients by the presence and type of hypothalamic-pituitary imaging abnormalities. This information may assist family counseling and patient management.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689058     DOI: 10.1159/000350829

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  18 in total

1.  Frequent development of combined pituitary hormone deficiency in patients initially diagnosed as isolated growth hormone deficiency: a long term follow-up of patients from a single center.

Authors:  Aline P Otto; Marcela M França; Fernanda A Correa; Everlayny F Costalonga; Claudia C Leite; Berenice B Mendonca; Ivo J P Arnhold; Luciani R S Carvalho; Alexander A L Jorge
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

2.  Brain Malformations Do Not Predict Hypopituitarism in Young Children with Optic Nerve Hypoplasia.

Authors:  Pamela Garcia-Filion; Hashem Almarzouki; Cassandra Fink; Mitchell Geffner; Marvin Nelson; Mark Borchert
Journal:  Horm Res Paediatr       Date:  2017-08-22       Impact factor: 2.852

3.  Early retesting by GHRH + arginine test shows normal GH response in most children with idiopathic GH deficiency.

Authors:  C Bizzarri; S Pedicelli; B Boscherini; G Bedogni; M Cappa; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

Review 4.  Advances in differential diagnosis and management of growth hormone deficiency in children.

Authors:  Camille Hage; Hoong-Wei Gan; Anastasia Ibba; Giuseppa Patti; Mehul Dattani; Sandro Loche; Mohamad Maghnie; Roberto Salvatori
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

5.  Prevalence of brain MRI findings in children with nonacquired growth hormone deficiency: a systematic review and meta-analysis.

Authors:  Jisun Hwang; Sang Won Jo; Eun Byul Kwon; Seun Ah Lee; Suk-Ki Chang
Journal:  Neuroradiology       Date:  2021-02-20       Impact factor: 2.804

Review 6.  Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the Genome Era.

Authors:  Qing Fang; Akima S George; Michelle L Brinkmeier; Amanda H Mortensen; Peter Gergics; Leonard Y M Cheung; Alexandre Z Daly; Adnan Ajmal; María Ines Pérez Millán; A Bilge Ozel; Jacob O Kitzman; Ryan E Mills; Jun Z Li; Sally A Camper
Journal:  Endocr Rev       Date:  2016-11-09       Impact factor: 19.871

7.  Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study.

Authors:  Cheri Deal; Susan Kirsch; Jean-Pierre Chanoine; Sarah Lawrence; Elizabeth Cummings; Elizabeth T Rosolowsky; Seth D Marks; Nan Jia; Christopher J Child
Journal:  CMAJ Open       Date:  2018-09-10

8.  Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD.

Authors:  Werner F Blum; George M Bright; Minh-Ha T Do; John C McKew; Haiying Chen; Michael O Thorner
Journal:  J Endocr Soc       Date:  2021-02-25

Review 9.  Growth hormone deficiency and replacement in children.

Authors:  Margaret C S Boguszewski
Journal:  Rev Endocr Metab Disord       Date:  2020-10-08       Impact factor: 6.514

Review 10.  The continuum between GH deficiency and GH insensitivity in children.

Authors:  Martin O Savage; Helen L Storr; Philippe F Backeljauw
Journal:  Rev Endocr Metab Disord       Date:  2020-10-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.